A1, an innovative fluorinated CXCR4 inhibitor, redefines the therapeutic landscape in colorectal cancer.

Cancer Cell Int · 2025 · PMC11702187 · PMID 39757159

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a decreasing trendno p-value reported

The per residue root mean square fluctuation (RMSF) values revealed a decreasing trend for CXCR4 in complex with A1 compared to those in complex with ITD, which shows the tighter intercalations of A1 with CXCR4 (Supplementary Information, Figure S5).

also in 47,180 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.